Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Ipilimumab + Chemotherapy in Resectable NSCLC
NCT07917767Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response Rate at 20 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07917767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917767.